Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 87
- Registration Number
- NCT00455858
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 330
- Registration Number
- NCT00447382
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 348
- Registration Number
- NCT00435019
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Norfolk, United Kingdom
Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis
Phase 3
Completed
- Conditions
- Postmenopausal Vaginal AtrophyMenopause
- Interventions
- Drug: estradiol, 10 mcg
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 336
- Registration Number
- NCT00431132
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 227
- Registration Number
- NCT00427154
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Phase 2
Completed
- Conditions
- Acquired Bleeding DisorderIntracerebral Haemorrhage
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 400
- Registration Number
- NCT00426803
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Newcastle Upon Tyne, United Kingdom
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Phase 2
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 564
- Registration Number
- NCT00422058
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Norwich, United Kingdom
Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00419718
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 196
- Registration Number
- NCT00411892
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin
Not Applicable
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT00410033
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Linköping, Sweden
© Copyright 2025. All Rights Reserved by MedPath